TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
SUNNYVALE, Calif. - BioCardia, Inc. (NASDAQ:BCDA), a micro-cap biotech company with a current market capitalization of $11.29 million, has been granted US Patent No. 12,311,127 for its "Radial and Trans-endocardial Delivery Catheter" technology, the company announced in a press release statement. According to InvestingPro data, the company’s stock is currently trading near its Fair Value.
The patent covers BioCardia’s minimally invasive interventional catheter systems designed to deliver biologic therapies to specific sites in the heart. The company’s helical needle-tipped catheter technology platform, known as the Helix system, allows for targeted treatment while minimizing off-target effects and avoiding surgical heart access. While the technology shows promise, InvestingPro analysis indicates the company is quickly burning through cash, with a weak financial health score of 1.48 out of 10.
According to the company, scientific literature supports that the Helix catheter system is among the safest and most efficient approaches for biotherapeutic delivery to the heart. The system is currently utilized in BioCardia’s CardiAMP Cell Therapy development program, which targets ischemic cardiomyopathies of heart failure and refractory angina.
"We are working diligently towards the separate approvals of the CardiAMP Cell Therapy as well as the Helix biotherapeutic delivery system it utilizes," said Dr. Peter Altman, BioCardia CEO.
BioCardia, headquartered in Sunnyvale, California, focuses on cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company has three clinical stage product candidates in development through its CardiAMP autologous and CardiALLO allogeneic cell therapy platforms.
The patent represents an important addition to BioCardia’s intellectual property portfolio as it continues development of its therapeutic platforms and delivery systems. With the stock trading at $2.18 and showing a -25.6% return over the past year, investors can access detailed analysis and 8 additional key insights through InvestingPro’s comprehensive research report, part of its coverage of over 1,400 US stocks.
In other recent news, BioCardia Inc. reported its financial results for the first quarter of 2025, showing a net loss of $2.7 million, up from $2.3 million in the same period the previous year. The company highlighted significant progress in its clinical trials, particularly the CARDI Amp heart failure trial, which demonstrated safety and meaningful benefits. BioCardia is also expanding into the electrophysiology market, aiming to leverage its unique cell therapy delivery systems. Despite financial constraints, the company raised additional capital through a modest financing effort with minimal dilution. BioCardia plans to submit the CARDI AMP HF results to the FDA and Japan’s PMDA, aiming for regulatory alignment. The company is actively enrolling patients in the CARDI AMP Heart Failure II trial and expects to deliver top-line data for BCDO2. BioCardia’s strategic focus on market expansion and clinical advancements has resulted in renewed investor interest, as reflected in the positive aftermarket response.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.